tiprankstipranks
Trending News
More News >
Liminatus Pharma, Inc. (LIMN)
NASDAQ:LIMN
US Market

Liminatus Pharma (LIMN) Income Statement

Compare
57 Followers

Liminatus Pharma Income Statement

Last quarter (Q3 2025), Liminatus Pharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Liminatus Pharma's net income was $-1.82M. See Liminatus Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 2.91M$ 2.59M$ 2.71M$ 2.53M$ 7.81K
Depreciation and Amortization
$ 0.00$ 0.00$ 0.00$ 0.00$ 7.81K
EBITDA
$ -2.75M$ -1.09M$ -2.71M$ 4.37M-
Operating Income
$ -2.91M$ -2.59M$ -2.71M$ -2.53M$ -7.81K
Other Income/Expenses
$ 20.86K$ 1.39M$ -219.00K$ 6.90M$ 0.00
Pretax Income
$ -2.89M$ -1.19M$ -2.93M$ 4.37M$ -7.81K
Net Income
$ -2.90M$ -1.23M$ -2.93M$ 4.37M$ -7.81K
Per Share Metrics
Basic EPS
$ -0.40$ -0.15$ -0.08$ 0.13$ 0.00
Diluted EPS
$ -0.40$ -0.15$ -0.08$ 0.13$ 0.00
Weighted Average Shares Outstanding
7.19M 8.01M 34.43M 34.50M 6.90M
Weighted Average Shares Outstanding (Diluted)
7.19M 8.01M 34.43M 34.50M 6.90M
Currency in USD

Liminatus Pharma Earnings and Revenue History